Kerwin E, Ferguson GT. An overview of glycopyrrolate/eFlow® CS in COPD. Expert Rev Respir Med. 2018 Jun;12(6):447-459. Available from: http://dx.doi.org/10.1080/17476348.2018.1476853
When the above article was first published online, contains visual artefacts and errors in two n values. Below is the corrected .
Figure 3. Placebo-adjusted, least squares mean change from baseline in SGRQ total scores in subjects receiving GLY 25 or 50 mcg b.i.d. in the GOLDEN 3 (a) and GOLDEN 4 (b) studies, and in subjects receiving GLY 50 mcg b.i.d. (57% of total population) or TIO 18 mcg q.d. (43% of total population) in the GOLDEN 5 study (c).
*p < 0.05; **p < 0.01 versus placebo b.i.d., twice daily; CI, confidence interval; GLY, glycopyrrolate; LSM, least squares mean; MCID, minimal clinically important difference; q.d., once daily; SE, standard error; SGRQ, St George’s respiratory questionnaire; TIO, tiotropium.
The authors apologise for this error.